# Arun Cancer Investigation - Progress

## Phase Overview

| Phase | Status | Date | Progress |
|-------|--------|------|----------|
| Phase 1: Research & Planning | Complete | 2026-01-16 | 100% |
| Phase 2: MCP Queries & Treatment Synthesis | Complete | 2026-02-01 | 100% |

---

## Phase 1: Research & Planning (2026-01-16) - COMPLETE

**Duration:** ~2 hours
**Status:** 100% - Comprehensive treatment research completed

### Objectives Achieved
- Researched EGFR exon 20/21 targeted therapies (2025-2026 evidence)
- Identified brain metastasis treatment options
- Compiled strategies to improve treatment outcomes
- Configured project-level MCPs for cancer investigation
- Created comprehensive treatment plan

### Research Deliverables

**Treatment Options Compiled:**
| Category | Options Identified |
|----------|-------------------|
| EGFR Exon 20 | Amivantamab, Sunvozertinib, Izalontamab |
| Brain Mets | Osimertinib, Furmonertinib, Zorifertinib |
| Combinations | Amivantamab + Lazertinib + Chemo |
| ADCs | Datopotamab deruxtecan, Patritumab deruxtecan |

**Improvement Strategies:**
- Molecular optimization (liquid biopsy, serial ctDNA)
- Treatment optimization (dose intensity, circadian timing)
- Supportive care (+2 months OS with early palliative care)
- Clinical trial access via regional centers

### Files Created
1. `.mcp.json` - 7 MCPs configured at project level
2. `context/claude.md` - Session context
3. `context/progress.md` - This file
4. `~/.claude/plans/gentle-mapping-feather.md` - Treatment plan

### Technical Setup
- Git repository initialized
- Project-level MCP configuration (not global per user preference)
- MCPs: cbioportal, chembl, pubmed, uniprot, reactome-server, clinicaltrials, pubchem

---

## Phase 2: MCP Queries & Treatment Synthesis (2026-02-01) - COMPLETE

**Duration:** ~1.5 hours
**Status:** 100% - Comprehensive treatment recommendations generated
**Commits:** 2 commits (bc5893d -> a534ea3)

### Clinical Update Received
- Ambulatory, eating/drinking well, disturbed sleep
- Brain metastasis (left temporal lobe) - SBRT completed, vision improved
- Systemic spread: liver, pelvis, parathoracic node
- Complicating factors: Heart failure, renal dysfunction, cytopenias

### MCP Queries Executed

| MCP | Queries | Key Findings |
|-----|---------|--------------|
| PubMed | 20+ searches | 210 cardiotoxicity, 170 T790M, 103 ICI myocarditis articles |
| ClinicalTrials | 12 geographic/targeted | 1,271+ trials in Singapore region |
| ChEMBL | 4 drug profiles | Osimertinib, carboplatin, pemetrexed, gemcitabine |
| cBioPortal | 2 searches | 41 lung cancer studies, EGFR gene (ID: 1956) |

### Key Evidence Compiled

**Cardio-Safe Options:**
- Carboplatin (preferred platinum)
- Lazertinib (cardio-safer than osimertinib - PMID 40919674)
- EGFR-TKIs (minimal cardiotoxicity)

**Renal Thresholds:**
- Pemetrexed: CrCl >= 45 mL/min required
- Carboplatin: Calvert formula dosing

**ICI in EGFR+:**
- Lower efficacy (10-20% vs 30-40%)
- Higher myocarditis risk with pre-existing cardiac disease

### Files Created
1. `2026-02-01_arun_treatment_recommendations.md` - 378 lines, comprehensive synthesis

### Repository
- Created: https://github.com/eesb99/Arun (private)
- 2 commits pushed to main

---

## Pending Work

### Phase 3: Lab-Based Personalization (Next Session)
- [ ] Receive current lab values (CBC, CMP, GFR)
- [ ] Calculate personalized carboplatin dose
- [ ] Determine pemetrexed eligibility
- [ ] Assess clinical trial eligibility
- [ ] Generate final treatment recommendation

### Patient Action Items
- [x] ~~Confirm exact EGFR mutation type with oncologist~~ (still needed)
- [ ] Obtain current CBC, CMP, eGFR from oncologist
- [ ] Request cardiology evaluation (LVEF, ECG)
- [x] ~~Contact regional cancer centers about clinical trials~~ (Singapore interest confirmed)

---

## Metrics

| Metric | Value |
|--------|-------|
| Sessions | 2 |
| Research topics | 10 (cardiotoxicity, nephrotoxicity, ICI safety, G-CSF, EGFR resistance, exon 20, brain mets, trials, drug profiles, genomics) |
| MCPs configured | 7 |
| MCP queries executed | 40+ |
| PubMed articles reviewed | 500+ |
| Clinical trials found | 1,271+ |
| Treatment options identified | 20+ |
| Output documents | 2 (plan + recommendations) |
